Enbrel® in Psoriatic Arthritis
This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Enbrel® in Psoriatic Arthritis|
- The proportion of subjects achieving a status on the Physician Global Assessment of Psoriasis of ""mild"" or better at week 24.
- Quality of life and disability as measured by the DLQI and HAQ
- Financial impact of therapy on disease as measured by Patient Pharmacoeconomic Questionnaire
- Serious Adverse Events
- Patient Global Assessment of Psoriasis
- Patient Global Assessment of Joint Disease
- Patient Global Assessment of Joint Pain
- Patient Assessment of Morning Stiffness Duration
Please refer to this study by its ClinicalTrials.gov identifier: NCT00111124